Latest stories on CABA
CABA Maintained by Citigroup -- Price Target Lowered to $8.00
GuruFocus38 · neutralanalyst
Cabaletta Bio Reports Durable Phase 1/2 Rese-cel Results
TipRanks64 · neutralproduct/pr
Cabaletta Bio, Inc. (CABA) files 8-K
SEC 8-K50 · neutralgeneral
Cabaletta Bio price target lowered to $8 from $10 at Citi
The Fly34 · bearishanalyst
Cabaletta Bio (CABA) Presents Promising Phase 1/2 Data on Rese-cel Therapy at ACR Convergence 2026
GuruFocus64 · neutralproduct/pr
Cabaletta Bio announces new Phase 1/2 data on rese-cel at ACR Convergence 2026
The Fly58 · neutralproduct/pr
Cabaletta Bio expects myositis topline results in second half of 2027
The Fly55 · neutralproduct/pr
Cabaletta Bio GAAP EPS of -$0.28 beats by $0.03
Business Insider63 · neutralearnings
Cabaletta Bio, Inc. (CABA) files 8-K
SEC 8-K50 · neutralgeneral
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
Business Insider58 · neutralearnings
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire58 · neutralearnings
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Cabaletta Bio to Participate in Upcoming Investor Conferences
Business Insider52 · neutralproduct/pr
Cabaletta Bio to Participate in Upcoming Investor Conferences
GlobeNewswire52 · neutralproduct/pr
BlackRock, Inc. Expands Cabaletta Bio Inc (CABA) Stake With 2.26 Million Share Purchase
GuruFocus58 · neutralgeneral
Cabaletta Bio: 40% Sell-Off Creates An Opportunity Despite Cash Concerns
Seeking Alpha63 · neutralanalyst
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire50 · neutralgeneral
Cabaletta Bio, Inc. (CABA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Seeking Alpha56 · neutralgeneral
Cabaletta Bio, Inc. (CABA) files 8-K
SEC 8-K50 · neutralgeneral
Cabaletta Bio to Participate in Upcoming Investor Conferences
StockTitan56 · neutralgeneral
Cabaletta Bio to Participate in Upcoming Investor Conferences
GlobeNewswire56 · neutralgeneral
Cabaletta Bio stock maintains Buy rating at TD Cowen on trial progress
Investing.com Analyst Ratings61 · neutralanalyst
Why is Cabaletta Bio stock sliding today?
Investing.com Markets34 · bearishgeneral